IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v124y2020i3p231-238.html
   My bibliography  Save this article

Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature

Author

Listed:
  • Morgan, Steven G.
  • Daw, Jamie R.
  • Greyson, Devon
  • Shnier, Adrienne
  • Holbrook, Anne
  • Lexchin, Joel

Abstract

Because not all medicines are equally safe, effective, and affordable, health systems often use formularies to define explicitly which medicines will be included and excluded from coverage.

Suggested Citation

  • Morgan, Steven G. & Daw, Jamie R. & Greyson, Devon & Shnier, Adrienne & Holbrook, Anne & Lexchin, Joel, 2020. "Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature," Health Policy, Elsevier, vol. 124(3), pages 231-238.
    • Handle: RePEc:eee:hepoli:v:124:y:2020:i:3:p:231-238
    DOI: 10.1016/j.healthpol.2019.12.010
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851019303045
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2019.12.010?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Rajan Ragupathy & Katri Aaltonen & June Tordoff & Pauline Norris & David Reith, 2012. "A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand," PharmacoEconomics, Springer, vol. 30(11), pages 1051-1065, November.
    2. Grepstad, Mari & Kanavos, Panos, 2015. "A comparative analysis of coverage decisions for outpatient pharmaceuticals: Evidence from Denmark, Norway and Sweden," Health Policy, Elsevier, vol. 119(2), pages 203-211.
    3. Carl Blankart & Tom Stargardt & Jonas Schreyögg, 2011. "Availability of and Access to Orphan Drugs," PharmacoEconomics, Springer, vol. 29(1), pages 63-82, January.
    4. Kesselheim, A.S. & Huybrechts, K.F. & Choudhry, N.K. & Fulchino, L.A. & Isaman, D.L. & Kowal, M.K. & Brennan, T.A., 2015. "Prescription drug insurance coverage and patient health outcomes: A systematic review," American Journal of Public Health, American Public Health Association, vol. 105(2), pages 17-30.
    5. Joshua Cohen & Laura Faden & Susan Predaris & Brian Young, 2007. "Patient access to pharmaceuticals: an international comparison," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(3), pages 253-266, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Douglas, Conor M.W. & Grunebaum, Shir, 2024. "Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada," Health Policy, Elsevier, vol. 143(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Apostolos Tsiachristas† & Ren頇oudriaan & Wim Groot, 2013. "The welfare effects of innovative pharmaceuticals: an international perspective from the Dutch experience," Applied Economics, Taylor & Francis Journals, vol. 45(9), pages 1219-1226, March.
    2. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
    3. Gleeson, Deborah & Lopert, Ruth & Reid, Papaarangi, 2013. "How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand," Health Policy, Elsevier, vol. 112(3), pages 227-233.
    4. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    5. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    6. Salas-Vega, Sebastian & Bertling, Annika & Mossialos, Elias, 2016. "A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK," Health Policy, Elsevier, vol. 120(10), pages 1104-1114.
    7. Bonastre, Julia & Chevalier, Julie & Van der Laan, Chantal & Delibes, Michel & De Pouvourville, Gerard, 2014. "Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals?," Health Policy, Elsevier, vol. 116(2), pages 162-169.
    8. Se Hee Lee & Seung-Lai Yoo & Joon Seok Bang & Jong Hyuk Lee, 2020. "Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007–2019)," IJERPH, MDPI, vol. 17(9), pages 1-8, April.
    9. Tuncel, Tuba, 2022. "Should We Prevent Off-Label Drug Prescriptions? Empirical Evidence from France," TSE Working Papers 22-1383, Toulouse School of Economics (TSE).
    10. Guo, Elaine Xiaoyu & Sweetman, Arthur & Guindon, G. Emmanuel, 2020. "Socioeconomic differences in prescription drug supplemental coverage in Canada: A repeated cross-sectional study," Health Policy, Elsevier, vol. 124(3), pages 252-260.
    11. Rajan Ragupathy & Katri Aaltonen & June Tordoff & Pauline Norris & David Reith, 2012. "A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand," PharmacoEconomics, Springer, vol. 30(11), pages 1051-1065, November.
    12. Enkelejda Avdi, 2013. "The Effect Of Pricing Policies And Cost-Containment Measures In Albanian Health Insurance Scheme," Romanian Economic Business Review, Romanian-American University, vol. 8(3), pages 61-78, September.
    13. Carl Blankart & Tom Stargardt & Jonas Schreyögg, 2011. "Availability of and Access to Orphan Drugs," PharmacoEconomics, Springer, vol. 29(1), pages 63-82, January.
    14. Melanie Büssgen & Tom Stargardt, 2023. "Does health technology assessment compromise access to pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 437-451, April.
    15. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
    16. Joshua Cohen, 2007. "Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 169-170, June.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:124:y:2020:i:3:p:231-238. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.